The Latest Cardiac and Vascular News
WAYNE, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today reported positive 12-month data from the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) designed to assess the safety and provide preliminary evidence of efficacy of lead gene therapy candidate XC001 (encoberminogene […]
PALO ALTO, Calif., July 17, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), is a commercial-stage biopharmaceutical company focused on genetic diseases and cancers. Today, alongside the dedicated physicians and courageous patients who participated, the Company reports positive results from ATTRibute-CM, its Phase 3 study […]
AALST, Belgium, July 17, 2023 (GLOBE NEWSWIRE) — PMcardio, a market leader in AI-powered cardiovascular diagnostics, is thrilled to announce a research and development partnership with the Cardiovascular Research Center Aalst, a world-renowned authority in cardiology. The transformative alliance blends PMcardio’s state-of-the-art technology with the globally acclaimed clinical expertise of the Aalst Center, […]
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced the publication of groundbreaking research in the journal Genes. The study titled “The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation” sheds light on the potential of […]
PALO ALTO, Calif.–(BUSINESS WIRE)–ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) are pleased to see the updated and expanded recommendations for the management of arterial hypertension that The European Society of Hypertension (ESH) presented at their 32nd annual European Meeting on Hypertension and Cardiovascular […]
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of breakthrough cardiovascular technologies, today announced enrollment completion in INFINITY-SWEDEHEART, a prospective, multicenter, single-blind, randomized clinical trial of the DynamX® Coronary Bioadaptor System, the first metallic coronary artery implant that adapts to vessel physiology versus the Resolute Onyx™ Drug-Eluting Stent (DES). DynamX Bioadaptor is the […]
PHOENIX–(BUSINESS WIRE)–Verve Medical, Inc. (Verve) announced today that the Company has received approval from the US Food & Drug Administration (FDA) to initiate its Natural Orifice via renal pelvis denervation (NOVEL- Denervation) Pivotal IDE trial for the treatment of uncontrolled hypertension to lower blood pressure. “This Pivotal trial is designed […]
LONDON, July 11, 2023 (GLOBE NEWSWIRE) — PMcardio, a leading force in AI-powered diagnostics for cardiovascular diseases, announces expansion into 15 additional European markets with the launch of its newest version. After a successful initial launch in the United Kingdom, with over 25 000 registered users, PMcardio is now making its […]
SOUTHLAKE, Texas, July 11, 2023 /PRNewswire/ — Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to RBT-1 for the reduction in risk of post-operative complications in patients undergoing cardiothoracic […]
DUBLIN–(BUSINESS WIRE)– FIRE1 today announced that the first U.S. patients have been successfully implanted with its FIRE1™ System for remote heart failure monitoring in an Early Feasibility Study. The study will assess FIRE1’s novel solution to improve outcomes for heart failure patients. The first patient was implanted at Austin Heart, Texas, where […]
